BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Post-marketing study data

Researchers at the University of California, San Francisco, reported data from a retrospective analysis of 84 MS patients who received >=12 infusions of Tysabri showing that 27.9% of patients who underwent a dosage interruption (n=68) experienced a clinical relapse within 6 months of the suspension, whereas no patients with ongoing treatment (n=16)...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >